KNOTUS Co., Ltd., Research Center, Incheon, Republic of Korea.
Department of Veterinary Medical Imaging, College of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
BMC Vet Res. 2022 Jun 22;18(1):237. doi: 10.1186/s12917-022-03324-2.
The aim of this study was to investigate the anti-obesity effects of DWP16001, a sodium-glucose cotransporter-2 (SGLT2 inhibitor), in naturally obese dogs. A total of 20 dogs were divided into four equal groups: one obese control (OC group), and three treated groups; DWP0.2 group, DWP0.5 group, and DWP1 group. OC group fed with food for maintenance and treated groups were fed with food for maintenance with 0.2 mg/kg DWP16001, 0.5 mg/kg DWP16001 and 1 mg/kg DWP16001, respectively. The food for maintenance was provided to dogs as 2 RER (Resting energy requirement) in kcal and DWP16001-supplemented food was administered once a day for 8 weeks.
Body condition score, body weight, and fat thickness were significantly reduced (P < 0.05) in the DWP0.2 group compared with the OC group, respectively without affecting the food consumption. At the 10 week the food consumption rate was 101.35 ± 2.56, 166.59 ± 4.72, 98.47 ± 1.44 and 123.15 ± 2.45% compared with initial food consumption rate. Body fat percentage, chest and waist circumference, blood glucose, and insulin were reduced compared to OC group but not significantly different from those of the OC group during experimental period. Serum alanine aminotransferase, alkaline phosphatase, creatine phosphokinase, and creatinine were significantly reduced in DWP0.2 group on 8 weeks. Serum cholesterol and triglycerides were reduced but not significantly. No specific adverse effects were observed throughout the experiment, and hematological parameters were unchanged. The results indicate that DWP16001 was not harmful to the dogs in our study and might have anti-obesity effects in naturally obese dogs.
The above results and discussion suggest that DWP16001 is safe and might have anti-obesity effects in naturally obese dogs.
本研究旨在探讨 DWP16001（一种钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂）对自然肥胖犬的抗肥胖作用。将 20 只犬随机分为 4 组，每组 5 只：肥胖对照组（OC 组）和 3 个治疗组；DWP0.2 组、DWP0.5 组和 DWP1 组。OC 组给予维持量食物，治疗组给予维持量食物，同时分别给予 0.2mg/kg、0.5mg/kg 和 1mg/kg 的 DWP16001。维持量食物按犬的 2 RER（静息能量需求）提供，DWP16001 补充食物每天一次，共 8 周。
与 OC 组相比，DWP0.2 组的体况评分、体重和脂肪厚度均显著降低（P<0.05），但不影响食物摄入量。第 10 周时，食物摄入量分别为初始食物摄入量的 101.35±2.56%、166.59±4.72%、98.47±1.44%和 123.15±2.45%。与 OC 组相比，DWP0.2 组的体脂百分比、胸围和腰围、血糖和胰岛素均有所降低，但在实验期间与 OC 组无显著差异。DWP0.2 组在第 8 周时，血清丙氨酸氨基转移酶、碱性磷酸酶、肌酸磷酸激酶和肌酐明显降低。血清胆固醇和甘油三酯有所降低，但无统计学意义。整个实验过程中未观察到特定的不良反应，血液学参数无变化。结果表明，在本研究中，DWP16001 对犬没有危害，可能对自然肥胖犬具有抗肥胖作用。
上述结果和讨论表明，DWP16001 安全，可能对自然肥胖犬具有抗肥胖作用。
